CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
Published on Β· Source: cnbc.com
AI Summary
Summarized by AI from the source belowCVS Health (CVS) announced the restoration of coverage for Eli Lilly's (LLY) Zepbound effective October 1 and will add the Foundayo obesity pill on June 1. This adjustment positions Lilly to compete equally with Novo Nordisk in the weight loss market, affecting an estimated 25 million to 30 million Americans. CVS aims for a 10% to 15% increase in savings across weight management treatments with the updated formulary. The decision follows a prior agreement with Novo Nordisk that made Wegovy the favored choice on CVS plans while previously excluding Zepbound.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About CVS Health Corporation (CVS)
CVS Health operates retail pharmacies, a pharmacy-benefits manager, and the Aetna insurance business.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier CVS news
- CVS Health (CVS) Stock Price Target Raised on Margin Recovery
- Market Outlook: Earnings Week Ahead for Major Techs and AMD
- US Health Insurers Surge on Medicare Payments Increasing 2.48%
- Eye Drops Recall Affects 3.1 Million Bottles Nationwide
- CVS Health Stock Maintains Outperform Rating Amid FTC Settlement Progress
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
BrainsWay Expands U.S. Insurance Coverage to 70M Lives
Oct 13
Kodiak Sciences (KOD) Target Raised by H.C. Wainwright on Trial Data
Oct 12
Medicare Advantage Plans Unavailable in 181 Counties by 2027
Oct 10
William Blair Downgrades Alignment Healthcare (ALHC) on Costs
Oct 9